Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients
- PMID: 15018734
- DOI: 10.1089/104303404322886101
Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients
Abstract
A phase I gene transfer clinical study was undertaken to examine the ability to introduce a potential anti-human immunodeficiency virus (HIV) gene therapeutic into hematopoietic progenitor cells (HPC), thereby contributing to multilineage engraftment. The potential therapeutic effect of genetically modifying HPC with protective genes in HIV-infected adults depends in part on the presence of adult thymic activity and myeloid capacity in the setting of HIV replication. Herein we report the presence and expression of a retroviral vector encoding an anti-HIV-1 ribozyme in mature hematopoietic cells of different lineages, and de novo T-lymphocyte development ensuing from genetically engineered CD34(+) HPC. Sustained output of vector-containing mature myeloid and T-lymphoid cells was detected even in patients with multidrug-resistant infection. In addition, the study showed that the degree of persistence of gene-containing cells was dependent on transduced HPC dose. These novel findings support the concept of gene therapy as a modality to effect immune reconstitution with cells engineered to inhibit HIV replication and this report represents the first demonstration of long-term maintenance of a potential therapeutic transgene in HIV disease.
Similar articles
-
Intracellular immunization of rhesus CD34+ hematopoietic progenitor cells with a hairpin ribozyme protects T cells and macrophages from simian immunodeficiency virus infection.Blood. 1997 Dec 15;90(12):4822-31. Blood. 1997. PMID: 9389699
-
Gene therapy targeting peripheral blood CD34+ hematopoietic stem cells of HIV-infected individuals.Hum Gene Ther. 1997 Dec 10;8(18):2229-38. doi: 10.1089/hum.1997.8.18-2229. Hum Gene Ther. 1997. PMID: 9449376
-
Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo.Mol Ther. 2000 Mar;1(3):244-54. doi: 10.1006/mthe.2000.0038. Mol Ther. 2000. PMID: 10933940
-
Development of HIV vectors for anti-HIV gene therapy.Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11395-9. doi: 10.1073/pnas.93.21.11395. Proc Natl Acad Sci U S A. 1996. PMID: 8876146 Free PMC article. Review.
-
siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.Anticancer Res. 2003 May-Jun;23(3A):1997-2005. Anticancer Res. 2003. PMID: 12894572 Review.
Cited by
-
Engineering of RNase P Ribozymes for Therapy against Human Cytomegalovirus Infection.Viruses. 2024 Jul 25;16(8):1196. doi: 10.3390/v16081196. Viruses. 2024. PMID: 39205170 Free PMC article. Review.
-
RNAi therapeutics: principles, prospects and challenges.Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):75-86. doi: 10.1016/j.addr.2007.03.005. Epub 2007 Mar 16. Adv Drug Deliv Rev. 2007. PMID: 17449137 Free PMC article. Review.
-
Development of hematopoietic stem cell based gene therapy for HIV-1 infection: considerations for proof of concept studies and translation to standard medical practice.Viruses. 2013 Nov 22;5(11):2898-919. doi: 10.3390/v5112898. Viruses. 2013. PMID: 24284880 Free PMC article. Clinical Trial.
-
Generation of T lineage cells from human embryonic stem cells in a feeder free system.Stem Cells. 2009 Jan;27(1):100-7. doi: 10.1634/stemcells.2008-0813. Stem Cells. 2009. PMID: 18974209 Free PMC article.
-
RNA Interference Therapies for an HIV-1 Functional Cure.Viruses. 2017 Dec 27;10(1):8. doi: 10.3390/v10010008. Viruses. 2017. PMID: 29280961 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
